Neurocrine registers Phase 1/2 gene therapy trial for Friedreich's Ataxia
Neurocrine Biosciences listed a first-in-human study of gene therapy NBIB-223 in Friedreich's Ataxia, not yet recruiting, with an estimated start of November 2026.
Neurocrine Biosciences had one registry update for the week, a new gene therapy trial for Friedreich's Ataxia.
- NBIB-0000223, an intravenous gene therapy, entered a Phase 1/2, dose-escalation study called "FACET" in patients with Friedreich's Ataxia. The record was first posted on 2026-11-12 with an estimated start of 2026-11 and estimated primary completion in 2028-111, and the study is not yet recruiting1. The trial plans to enroll 24 participants across three parts covering dose escalation in adults, dose expansion in pediatric participants, and dose expansion in participants with FA-related cardiomyopathy1, with sites located at 5 sites in the United States, including Los Angeles, Gainesville, Tampa, Iowa City, and Philadelphia1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.